Ranbaxy hits 52-week high, surges 8% in two days
The company has withdrawn 27 drugs from the US market due to commercial reasons.
Ranbaxy Laboratories has rallied 4% at Rs 554, extending its previous day’s over 4% surge after the pharmaceutical firm said that it had withdrawn 27 drugs from the US market due to commercial reasons.
“The company has determined certain products with negligible commercial impact should be withdrawn to enable it to focus resources on other applications of greater importance and value to the US business and health care system,” Ranbaxy said in a filing to the Bombay Stock Exchange.
Analysts said the move would not have a significant impact on Ranbaxy’s future revenues as it was already not allowed to sell those drugs in the US.
The stock opened at Rs 541 and hit a low of Rs 536 on the NSE. A combined 1.65 million shares have already changed hands on the counter till early noon deals, against an average 1.32 million shares that were traded daily in past two weeks.
Source: Business Standard
Similar Posts:
- Reliance Industries will buy the Hotel Leelaventure’s business park in Chennai -Hotel Leelaventure surges on heavy volumes
- Biocon hits 52-week high on DCGI nod to market biosimilar trastuzumab in India
- Jet Airways rallies on regulatory nod to Etihad for stake buy in Jet unit
- Bharti Airtel surges 8% after 9% fall in two days
- Aviation shares rally on heavy volumes, Jet Airways surges 15%
Latest Query
- by Sam
Market Stats
Search Our Archives
Research Desk
- Stocks Trading above their 50 day moving average - DMA In Stock Research
- Download free Ebooks based on Technical Analysis In Personal Training
- TOP 100 Stocks with the Highest P/E as on July 14th, 2013 In Stock Research
- TOP 100 Stocks with the Lowest P/E as on July 14th, 2013 In Stock Research
- Charting Pathsala - Your guide to Techincals In Technical Analysis
